HONG KONG – South Korea's JW Pharmaceutical Corp. out-licensed its atopic dermatitis candidate, JW-1601, to Danish medical dermatologist Leo Pharma A/S, which has rights to develop and commercialize the drug worldwide, except in South Korea.